As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Erasca, Inc. The largest reported stake is Jonathan E. Lim's, at 10.4%. 13 filings are on record since August 13, 2025 (Schedule 13G/A, August 14, 2026).
Sell to companies like Erasca, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: City Hill, LLC · Sole voting: 0 · Shared voting: 12,899,360 · Sole dispositive: 0 · Shared dispositive: 12,899,360 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Paradigm BioCapital Advisors LP · Percent: 3.3% · SCHEDULE 13G/A
- · Holder: RTW Investments, LP · Percent: 5.2% · SCHEDULE 13G
- · Holder: Venrock Healthcare Capital Partners III, L.P. · Percent: 5.3% · SCHEDULE 13G/A
- · Holder: T. Rowe Price Investment Management, Inc. · Percent: 6.8% · SCHEDULE 13G/A
Erasca, Inc. has 13 Schedule 13D or 13G filings on record since 2025-08-13. 5 holders' latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 10.4% | 36,968,486 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 | |
| T. Rowe Price Investment Management, Inc. | 6.8% | 21,224,264 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Frazier Life Sciences Public Fund, L.P. | 5.3% | 15,038,753 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Venrock Healthcare Capital Partners III, L.P. | 5.3% | 16,382,812 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| RTW Investments, LP | 5.2% | 16,157,175 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| Logos Global Management LP | 4.8% | 13,600,000 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Paradigm BioCapital Advisors LP | 3.3% | 10,392,702 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Suvretta Capital Management, LLC | 1.1% | 3,434,967 | SCHEDULE 13G/A, 2026-05-12 | 2026-03-31 |
Holding shares or following this stake? See who's behind Erasca, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Erasca, Inc. and the records around it.
Erasca, Inc. elsewhere on the record
- Leadership changes Aug 2026
- Who owns it
Companies that share a holder
- Logos Global Management LP also filed stake reports on 14 other companies: Longeveron Inc. (Sep 2026), ACHIEVE LIFE SCIENCES, INC. (Aug 2026), Yarrow Bioscience, Inc. (Aug 2026)
- Paradigm BioCapital Advisors LP also filed stake reports on 22 other companies: Obsidian Therapeutics, Inc. (Oct 2026), Spyre Therapeutics, Inc. (Oct 2026), Tyra Biosciences, Inc. (Sep 2026)
- Suvretta Capital Management, LLC also filed stake reports on 22 other companies: Veradermics, Inc (Aug 2026), Abeona Therapeutics Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
Watch Erasca, Inc.
Get an email when Erasca, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Erasca, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Erasca, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Erasca, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| City Hill, LLC | 0 | 12,899,360 | 0 | 12,899,360 | SCHEDULE 13G/A, 2026-08-14 |
| Jonathan E. Lim | 4,612,910 | 32,355,576 | 4,612,910 | 32,355,576 | SCHEDULE 13G/A, 2026-08-14 |
| Conyee T. Lim | 0 | 19,456,216 | 0 | 19,456,216 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Erasca, Inc. by CUSIP 29479A108 and gives its principal executive office as 3115 Merryfield Row, Suite 300, San Diego, CA 92121 (SCHEDULE 13G/A, 2026-08-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-13 | Suvretta Capital Management, LLC | 5.1% | SCHEDULE 13G |
| 2025-08-14 | Logos Global Management LP | 5.3% | SCHEDULE 13G |
| 2025-08-14 | Frazier Life Sciences Public Fund, L.P. | 5.3% | SCHEDULE 13G/A |
| 2025-08-14 | T. Rowe Price Investment Management, Inc. | 7.2% | SCHEDULE 13G/A |
| 2025-11-14 | Logos Global Management LP | 4.8% | SCHEDULE 13G/A |
| 2026-01-14 | Paradigm BioCapital Advisors LP | 5.3% | SCHEDULE 13G |
| 2026-02-17 | T. Rowe Price Investment Management, Inc. | 5.7% | SCHEDULE 13G/A |
| 2026-05-12 | Suvretta Capital Management, LLC | 1.1% | SCHEDULE 13G/A |
| 2026-05-15 | Paradigm BioCapital Advisors LP | 3.3% | SCHEDULE 13G/A |
| 2026-05-15 | RTW Investments, LP | 5.2% | SCHEDULE 13G |
| 2026-05-15 | Venrock Healthcare Capital Partners III, L.P. | 5.3% | SCHEDULE 13G/A |
| 2026-05-15 | T. Rowe Price Investment Management, Inc. | 6.8% | SCHEDULE 13G/A |
| 2026-08-14 | Jonathan E. Lim | 10.4% | SCHEDULE 13G/A |
Questions about who owns Erasca, Inc.
Who owns Erasca, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Erasca, Inc.: Jonathan E. Lim (10.4%, Schedule 13G/A, filed 2026-08-14), T. Rowe Price Investment Management, Inc. (6.8%, Schedule 13G/A, filed 2026-05-15), Frazier Life Sciences Public Fund, L.P. (5.3%, Schedule 13G/A, filed 2025-08-14), Venrock Healthcare Capital Partners III, L.P. (5.3%, Schedule 13G/A, filed 2026-05-15) and RTW Investments, LP (5.2%, Schedule 13G, filed 2026-05-15).
Who are the largest shareholders of Erasca, Inc.?
By the share each holder's latest filing reports, the largest holders of Erasca, Inc. on this page are Jonathan E. Lim (10.4%), T. Rowe Price Investment Management, Inc. (6.8%) and Frazier Life Sciences Public Fund, L.P. (5.3%).
When did Jonathan E. Lim buy into Erasca, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Jonathan E. Lim on this page is the Schedule 13G/A, filed 2026-08-14, reporting 10.4%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 13 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Erasca, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 16, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| August 10, 2026 | Leadership change: Charles S. Fuchs appointed, President | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Erasca, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.